The role of mycophenolate in the treatment of antineutrophil cytoplasmic antibody-associated vasculitis

Table 1 Mycophenolic acid for induction treatment in antineutrophil cytoplasmic antibody-associated vasculitis

Authors	Yr	Study design	No Pt	Diagnosis	ANCA	Follow-up in mo	Remission rate
Joy et al[6]	2005	Case series	12	WG: 7, MPA: 2, Renal Limited: 2; CS:1	MPO: 3, PR3: 9	12	6/10 - 60%
Koukoulaki et al[12]	2006	Case series	22	N/A	N/A	24	18/22 – 81.8%
Stassen et al[15]	2007	Cohort	32	MPA: 3; WG: 29	MPO: 3; PR3: 29	48	Complete remission: 25/32 - 78%; Partial remission: 6/32 - 19%
Hu et al[7]	2008	Randomized	35	N/A	MPO: 28; PR3: 2	6	Mycophenolate: 77.8% (14/18); CYC: 61.5% (8/13)
Silva et al[16]	2010	Cohort	17	MPA: 17	MPO: 17	18	Remission at 6 mo: 13/17 - 76%; Sustained remission at 18 mo: 12/17 - 70%
Han et al[8]	2011	Randomized	42	N/A	MPO: 42	6	Mycophenolate: 78.9% (14/18); CYC: 63.6% (8/13)
Jones et al[9]	2018	Randomized	140	MPA: 49; GPA: 91	MPO: 53; PR3: 82	18	Mycophenolate: 67% (47/70); CYC:61% (43/70)
Chen et al[17]	2016	Cohort	34	MPA: 34	MPO: 34	86	31/34 - 91.2%

ANCA: Antineutrophil cytoplasmic antibody; AZA: Azathioprine; CYC: Cyclophosphamide; MPA: Microscopic polyangiitis; MPO: Myeloperoxidase; No: Number; N/A: Not available; PR3: Proteinase 3; Pt: Patients; WG: Wegener’s granulomatosis.